Novo Nordisk, semaglutide

Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief executive of Ozempic maker Novo Nordisk warned Wednesday.
Novo Nordisk CEO warns of deaths linked to compounded semaglutide
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least 100 hospitalizations and 10 deaths.
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the FDA to resolve issues.
Novo Nordisk will file semaglutide for MASH next year
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and European regulatory filings in the first half of next year.
Compounded Ozempic tied to deaths, hospitalizations: Novo Nordisk CEO
Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October requested the FDA block compounding pharmacies from producing versions of the drug, saying semaglutide is too complex for others to replicate safely.
Aware Of 10 Deaths Linked To Compounded Semaglutide Intake: Novo Nordisk
Danish pharma giant Novo Nordisk has said it is aware of at least 10 deaths and 100 hospitalisations linked to compounded versio
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
Outsourcing-pharma3d
Novo Nordisk’s semaglutide shows additional cardiovascular benefits in overweight patients
Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...
GlobalData on MSN4d
Novo Nordisk reports positive data from part one of semaglutide trial for MASH
Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...
FiercePharma7d
Novo Nordisk's semaglutide delivers in phase 3 MASH study, teeing up filings
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...
FierceBiotech2d
Novo Nordisk discards kidney disease drug from $1.3B deal in wake of phase 3 fail
Novo Nordisk, after mulling the implications of a phase 3 fail ... With ocedurenone gone, the only CKD program still ...
Novo Nordisk Posts Mixed Results, Adding to Jitters About Weight-Loss Drugs
A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may ...